A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Phase 1

Recruiting

• Conditions: Recurrent Genital Herpes Simplex Type 2
• Interventions: Drug: ABI-1179; Drug: ABI-1179 Placebo

• Registration Number: NCT06698575
• Lead Sponsor: Assembly Biosciences

Brief Summary

This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-10
• Study First Submitted: 2024-11-08
• Study First Submitted QC: 2024-11-18
• Study First Posted: 2024-11-21
• Study Start: 2024-12-08
• Last Update Submitted: 2025-03-26
• Last Update Posted: 2025-03-27
• Primary Completion: 2025-11
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

• Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2
• In good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
• Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day-1 or Day 1 (predose).
• Agreement to comply with protocol-specified contraceptive requirements.

Part B: Inclusion Criteria:

• Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2
• Other than HSV infection, is in good health (as determined by the investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
• Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 (predose).
• Agreement to comply with protocol-specified contraceptive requirements

Part A and B:

Exclusion Criteria

• Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV), hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV).
• History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or condition known to interfere with the absorption /distribution/ elimination of drugs.
• History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson Syndrome, urticaria, or multiple drug allergies.
• History of persistent alcohol abuse or illicit drug abuse within 3 years prior to screening.
• Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before screening, whatever is longer.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Part A: SAD Cohorts 1-5, ABI-1179	ABI-1179	Single dose of ABI-1179 (tablet) in Part A for cohorts 1-5
Part A: SAD Cohorts 1-5, ABI-1179	ABI-1179 Placebo	Single dose of ABI-1179 (tablet) in Part A for cohorts 1-5
Part A:SAD Cohorts 1-5, Placebo	ABI-1179	Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
Part A:SAD Cohorts 1-5, Placebo	ABI-1179 Placebo	Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
Part A: (SAD) Fed Cohort 6 or 7, ABI-1179	ABI-1179	Single dose of ABI-1179 (tablet) in Part A for Cohort 6 or 7, food effect
Part A: (SAD) Fed Cohort 6 or 7, ABI-1179	ABI-1179 Placebo	Single dose of ABI-1179 (tablet) in Part A for Cohort 6 or 7, food effect
Part B: MAD Cohorts 1-4, ABI-1179	ABI-1179	Weekly dose ofABI-1179 (tablet) in Part B for Cohorts 1-4. May have loading dose.
Part B: MAD Cohorts 1-4, ABI-1179	ABI-1179 Placebo	Weekly dose ofABI-1179 (tablet) in Part B for Cohorts 1-4. May have loading dose.
Part B: MAD Cohorts 1-4 Placebo	ABI-1179	Weekly dose of matching placebo (tablet) in Part B for Cohorts 1-4.
Part B: MAD Cohorts 1-4 Placebo	ABI-1179 Placebo	Weekly dose of matching placebo (tablet) in Part B for Cohorts 1-4.

Primary Outcome Measures

Name	Time	Method
Maximum Observed Plasma Concentration (Cmax) of ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Time to Cmax (Tmax) of ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Apparent Terminal Elimination Half Life ( t 1/2) ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Apparent Systemic Clearance (CL/F) of ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Area Under the Plasma Concentration Time Curve, (AUC) of ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Apparent Volume of Distribution (Vz/F) of ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Dose normalized AUCs and Cmax of ABI-1179	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.
Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AE's and abnormal laboratory results.	Up to 56 days after last dose.

Secondary Outcome Measures

Name	Time	Method
SAD Cohorts: Comparison of Plasma AUC between fasted and fed treatments	MAD Cohorts: At pre-specified time points from Days 8 to 36.
SAD Cohorts: Comparison of plasma Cmax between fasted and fed treatments	SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing.
MAD Cohort: If applicable comparison of plasma AUC and Cmax with and without loading doses	MAD Cohorts At pre-specified timepoints from Days 8 to 36
MAD Cohorts: Difference in viral shedding rate (number of anogenital swabs positive for HSV-2 DNA/total number of swabs) across treatments.	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: in mean and median HSV-2 DNA copies/ml for swab samples positive for HSV-2 DNA across treatments	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in the proportion of swab samples with HSV-2 DNA>4log10 copies/mL across treatments (number of swabbing samples with HSV-2 DNA >4 log10 copies/mL / total number of swabs obtained).	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in number of shedding episodes during the swabbing period across treatments.	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in duration of shedding episodes during the swabbing period across treatments.	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in the subclinical shedding rate (number of swabs positive for HSV-2 DNA in the absence of lesions/total number of swabs in the absence of lesions) across treatments.	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in the lesion rate during the swabbing period across treatments.	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in lesion duration during the swabbing period across treatments	MAD Cohorts: At pre-specified time points from Days 8 to 36.
MAD Cohorts: Difference in the recurrence rate (number of reappearances of lesions during the swabbing period/total days assessed) across treatments.	MAD Cohorts: At pre-specified time points from Days 8 to 36.

Trial Locations

Locations (9)

Momentum Sunshine; 🇦🇺 Melbourne, Au, Australia

East Sydney Doctors; 🇦🇺 Darlinghurst, Australia

New Zealand Clinical Research; 🇳🇿 Christchurch, New Zealand

Royal Melbourne Hospital; 🇦🇺 Parkville, Australia

Pacific Clinical Research Network; 🇳🇿 Upper Hutt, New Zealand

Momentum Palmerston North; 🇳🇿 Palmerston North, New Zealand

Momentum Kapiti; 🇳🇿 Waikanae, New Zealand

Taylor Square Private Clinic; 🇦🇺 Surry Hills, Australia

Momentum Clinical Research; 🇦🇺 Sydney, Australia